Sanofi (NASDAQ:SNY - Get Free Report) has earned an average recommendation of "Moderate Buy" from the four analysts that are presently covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $57.50.
SNY has been the topic of a number of research reports. Argus raised their price target on Sanofi from $55.00 to $60.00 and gave the stock a "buy" rating in a research note on Friday, July 26th. StockNews.com upgraded Sanofi from a "buy" rating to a "strong-buy" rating in a research note on Wednesday. Finally, Citigroup upgraded Sanofi to a "strong-buy" rating in a research note on Tuesday, September 17th.
Read Our Latest Stock Analysis on SNY
SNY opened at $53.27 on Friday. The stock's 50-day moving average price is $55.92 and its 200 day moving average price is $52.00. Sanofi has a 12-month low of $45.00 and a 12-month high of $58.97. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. The firm has a market cap of $135.19 billion, a price-to-earnings ratio of 27.18, a PEG ratio of 1.35 and a beta of 0.61.
Sanofi (NASDAQ:SNY - Get Free Report) last issued its quarterly earnings results on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, topping the consensus estimate of $0.22 by $1.35. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The company had revenue of $13.44 billion for the quarter, compared to the consensus estimate of $16.59 billion. During the same quarter in the prior year, the business earned $2.55 EPS. Sanofi's revenue was up 12.3% on a year-over-year basis. As a group, sell-side analysts expect that Sanofi will post 4.27 earnings per share for the current year.
Several hedge funds have recently modified their holdings of SNY. POM Investment Strategies LLC acquired a new position in Sanofi during the second quarter worth $25,000. Larson Financial Group LLC raised its holdings in Sanofi by 480.8% during the first quarter. Larson Financial Group LLC now owns 604 shares of the company's stock worth $29,000 after purchasing an additional 500 shares during the last quarter. Northwest Investment Counselors LLC acquired a new position in Sanofi during the third quarter worth $29,000. Concord Wealth Partners raised its holdings in Sanofi by 157.8% during the third quarter. Concord Wealth Partners now owns 593 shares of the company's stock worth $34,000 after purchasing an additional 363 shares during the last quarter. Finally, Arrow Financial Corp acquired a new position in Sanofi during the second quarter worth $35,000. 10.04% of the stock is owned by institutional investors and hedge funds.
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Sanofi, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanofi wasn't on the list.
While Sanofi currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.